CorMedix (CRMD) Expected to Announce Quarterly Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $27.46 million for the quarter.

CorMedix Price Performance

CRMD opened at $10.71 on Friday. The company’s 50 day simple moving average is $10.54 and its two-hundred day simple moving average is $9.51. CorMedix has a 1-year low of $3.03 and a 1-year high of $13.85. The firm has a market capitalization of $649.85 million, a price-to-earnings ratio of -13.22 and a beta of 1.53.

Analysts Set New Price Targets

Several analysts have recently commented on CRMD shares. Leerink Partnrs raised shares of CorMedix to a “strong-buy” rating in a research report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of CorMedix in a research report on Wednesday. Royal Bank of Canada lifted their price target on shares of CorMedix from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, December 19th. Finally, Leerink Partners started coverage on shares of CorMedix in a research report on Friday. They set an “outperform” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.